Hartaj Singh
Stock Analyst at Oppenheimer
(1.37)
# 3,394
Out of 4,876 analysts
103
Total ratings
37.25%
Success rate
-12.1%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $123 → $45 | $17.11 | +163.00% | 11 | Jun 20, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $521.00 | +72.74% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $110.67 | +12.95% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $441.30 | - | 17 | Dec 19, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $5.57 | +402.69% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $284.27 | +111.07% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $27.16 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.47 | +580.27% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.81 | +3,214.92% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.94 | +363.92% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $2.11 | +1,795.73% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $6.93 | +217.46% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.95 | +33,233.33% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $20.60 | +45.63% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jun 20, 2025
Maintains: Outperform
Price Target: $123 → $45
Current: $17.11
Upside: +163.00%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $521.00
Upside: +72.74%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $110.67
Upside: +12.95%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $441.30
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $5.57
Upside: +402.69%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $284.27
Upside: +111.07%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $27.16
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.47
Upside: +580.27%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.81
Upside: +3,214.92%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.94
Upside: +363.92%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $2.11
Upside: +1,795.73%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $6.93
Upside: +217.46%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.95
Upside: +33,233.33%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $20.60
Upside: +45.63%